ACM
UNCY icon

Altium Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Altium Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-147,300
Closed -$1.17M – 67
2024
Q4 		$1.17M Hold
147,300
– – 0.33% 54
2024
Q3 		$601K Buy
+147,300
New +$592K 0.18% 54

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Altium Capital Management's UNCY Position: Q1 2025 in Review

Altium Capital Management sold out of Unicycive Therapeutics (UNCY) in Q1 2025, closing a stake of 147,300 shares — an estimated $1.17M sold.

Altium Capital Management first reported a position in UNCY in Q3 2024 and held it in 2 quarters. The position peaked at $1.17M in Q4 2024. 29 funds tracked by Wall St. Rank hold UNCY as of Q1 2025.

  • Altium Capital Management reported no remaining Unicycive Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 147,300 Unicycive Therapeutics shares in Q1 2025, an estimated $1.17M.
  • Altium Capital Management first reported a position in Unicycive Therapeutics in Q3 2024 and held it in 2 quarters.
  • Altium Capital Management's Unicycive Therapeutics position peaked at $1.17M in Q4 2024.
  • 29 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.